Abbott’s Xience family of stents received U.S. Food and Drug Administration approval for one-month (as short as 28 days) dual anti-platelet therapy labeling for high bleeding risk patients in the United States.
Bristol Myers Squibb Co. reported lower-than-expected first-quarter profit on April 29 as sales of the company’s high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.
A judge in Hawaii ordered Bristol-Myers Squibb Co. and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from the blood thinner Plavix.
The likelihood that a coronavirus infection will prove fatal dropped by nearly a third since April due to improved treatment, researchers at the University of Washington’s Institute for Health Metrics and Evaluation (IHME) said.
The painkiller aspirin will be evaluated as a possible treatment for Covid-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.
Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.
The National Institutes of Health launched two of the three late-stage clinical trials to test the effectiveness and safety of different types of blood thinners in treating Covid-19 among adults.
A federal court upheld patent claims regarding Bristol Myers Squibb and Pfizer’s Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.
The National Institutes of Health (NIH) announced plans to launch a “flurry” of large-scale clinical trials for treating Covid-19.
The U.S. Food and Drug Administration approved the first generic version of Bristol-Myers Squibb Co. and Pfizer Inc.’s blood thinner Eliquis.